Cyclodialysis Procedure with Scleral Reinforcement Effectively Lowers IOP in Open-Angle Glaucoma

巩膜加固睫状体透析术可有效降低开角型青光眼的眼压

December 31, 2024

2024年12月31日

A recent study published in Clinical Ophthalmology demonstrated that a bio-interventional cyclodialysis procedure with allograft scleral reinforcement significantly lowered intraocular pressure (IOP) in patients with open-angle glaucoma by enhancing uveoscleral outflow. The procedure utilized the CycloPen microinterventional system and AlloFlo, both developed by Iantrek..

最近发表在《临床眼科学》上的一项研究表明，同种异体巩膜加固的生物介入性睫状体透析手术通过增强葡萄膜巩膜流出而显着降低开角型青光眼患者的眼压（IOP）。该程序使用了由Iantrek开发的CycloPen微介入系统和AlloFlo。。

The study, led by Robert N. Weinreb, MD, focused on the safety and efficacy of this innovative approach in glaucoma patients undergoing cataract surgery.

这项由医学博士RobertN.Weinreb领导的研究集中于这种创新方法在接受白内障手术的青光眼患者中的安全性和有效性。

Methodology

方法论

The analysis included data from 117 eyes enrolled in the CREST Real-World Evidence interventional study, with a follow-up period of one year. Key metrics evaluated included IOP levels and the number of IOP-lowering medications used.

该分析包括参加CREST真实世界证据介入研究的117只眼睛的数据，随访期为一年。评估的关键指标包括眼压水平和使用的降低眼压药物的数量。

Baseline Characteristics

基线特征

• Mean Medicated IOP: 20.2 ± 6.0 mm Hg

•平均药物眼压：20.2±6.0 mm Hg

• Mean Number of Medications: 1.4 ± 1.3

•平均药物数量：1.4±1.3

Key Results

主要成果

IOP Reduction and Medication Use

眼压降低和药物使用

At 12 months post-surgery:

手术后12个月：

• Mean IOP: Reduced to 13.9 ± 3.9 mm Hg.

•平均眼压：降至13.9±3.9 mm Hg。

• Medication Use: Reduced to 0.8 ± 0.9 medications.

•药物使用：减少到0.8±0.9药物。

• Success Rate: 81.9% of patients achieved a medicated IOP of ≤18 mm Hg while maintaining or reducing their medication usage.

•成功率：81.9%的患者在维持或减少药物使用的同时达到≤18 mm Hg的药物眼压。

Safety Profile

安全简介

The procedure exhibited a favorable safety profile with a low rate of complications:

该手术表现出良好的安全性，并发症发生率低：

• Postoperative Complications: Minimal, with no vision-threatening adverse events reported.

•术后并发症：最小，无视力威胁不良事件报告。

• Secondary Glaucoma Surgeries: Required in only 3.2% of patients.

•继发性青光眼手术：仅3.2%的患者需要。

Conclusion

结论

The combination of cyclodialysis with scleral reinforcement using CycloPen and AlloFlo offers a promising approach for IOP management in patients with open-angle glaucoma. The procedure not only achieved significant IOP reductions but also reduced dependence on medications, all while maintaining a strong safety profile..

使用CycloPen和AlloFlo将睫状体透析与巩膜加固相结合，为开角型青光眼患者的眼压管理提供了一种有前途的方法。该手术不仅显着降低了眼压，而且减少了对药物的依赖，同时保持了良好的安全性。。

This bio-interventional strategy could become a valuable addition to the treatment options available for glaucoma patients, particularly those undergoing cataract surgery. Further studies may help solidify its role in clinical practice.

这种生物介入策略可能成为青光眼患者可用治疗选择的有价值的补充，特别是那些接受白内障手术的患者。进一步的研究可能有助于巩固其在临床实践中的作用。

Resource:

资源：

https://www.tandfonline.com/doi/full/10.2147/OPTH.S496631#d1e300

https://www.tandfonline.com/doi/full/10.2147/OPTH.S496631#d1e300